DCarpets called immune checkpoint inhibitors have transformed the treatment of many types of tumors, but metastatic lung cancer has proven to be more challenging: While these drugs have significantly extended the survival of some patients, most still do not respond or builds resistance quickly. Now a little proof of concept study published in Nature Medicine shows that a new form of immunotherapy that uses a patient’s own immune cells can produce long-lasting responses for some people with advanced non-small cell lung cancer (NSCLC).
Patients in the small phase 1 pilot trial were treated with tumor infiltrating lymphocytes (TILs), which had previously produced long-lasting remissions in studies of patients with some other cancers, but had not been previously tested in metastatic lung cancer. TILs are naturally found in solid tumors and have the ability to kill cancer cells, but the body does not make enough of them. The researchers then removed the cells from the tumors and grew billions of copies in laboratory dishes before transferring them back to patients.
What is?
STAT + is STAT’s premium subscription service for comprehensive biotech, pharmacy, policy and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early scientific advances and clinical trial results, and the disruption of healthcare in Silicon Valley and beyond.
What is included?
- Daily reports and analysis
- The most comprehensive industry coverage from a powerful team of reporters
- Subscriber-only newsletters
- Daily newsletters to inform you of the most important industry news of the day.
- STAT + Conversations
- Weekly opportunities to interact with our industry leading reporters and experts in live video conversations.
- Industry exclusive events
- Premium access to subscriber-only networking events nationwide
- The best reporters in the industry
- The healthcare industry’s most trusted and best-connected newsroom
- And much more
- Exclusive interviews with industry leaders, profiles and premium tools, like our CRISPR Trackr.